Apex Labs Ltd., a pharmaceutical company at the forefront of mental health treatment using psilocybin, is excited to announce the submission of a provisional patent application to the United States Patent and Trademark Office (USPTO). This application relates to APEX's specially formulated capsule intended for use in the PATHFINDER-52 and SUMMIT-90 phase 2b clinical trials, as well as in APEX's Early Access Program (EAP). Extensive research data supports APEX's innovative approach, which enhances the bioavailability, oxidative stability, and thermal stability of psilocybin and other psychedelics across different dosage levels.

Tyler Powell, CEO and Co-Founder, commended the APEX research and development team for their dedication in developing this advanced drug delivery system. He emphasized the importance of this patent application as a key element of APEX's intellectual property strategy, ensuring the company's commercial success.

In the first quarter of 2024, APEX obtained its Controlled Drugs and Substances Dealer's Licence (DL), allowing the company to distribute APEX drugs through Health Canada's Special Access Program (SAP), thereby providing access to treatment for Canadians outside of clinical trials.

Dr. Orion Lekos, Chief Science Officer and Co-Founder, praised the team's efforts in reaching this milestone in the drug development process. He highlighted the significance of the unique capsule in enabling dosing both in clinical settings and at home, expressing confidence in the enhanced bioavailability and efficacy of APEX's drug assets, which he believes will establish APEX as a leader in the field.

 

Source: prnewswire.com

Report Abuse